Evidence map›Paper›PMID 37567783›Full record

ArticleMolecular pharmacology2023

G

Rana Alabdali, Luca Franchini, Cesare Orlandi

Open access · hybridAbstract read
In one paragraph

Article in Molecular pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. G protein signaling capabilities at the bradykinin 2 receptor.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  2. G protein signaling capabilities at the bradykinin 2 receptor.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  3. Review
  4. Article
  5. Serotonin 5-HTACS chemical neuroscience · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. GNature communications · 2025
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rana AlabdaliDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY.
Luca FranchiniDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY.
Cesare OrlandiDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY cesare_orlandi@urmc.rochester.edu.ORCID 0000-0002-4992-9350
University of Rochester Medical Center · US

Funding

Orphan Receptor Gprc5b in Retinoic Acid-induced Affective BehaviorsR03TR003621 · NCATS · UNIVERSITY OF ROCHESTER · PI ORLANDI, CESARE · 2022 to 2022
$154k
NCATS NIH HHS R03 TR003621
6 · The paper itself

Abstract

Serotonin 1A receptor (5-HT1AR) is a clinically relevant target because of its involvement in several central and peripheral functions, including sleep, temperature homeostasis, processing of emotions, and response to stress. As a G protein coupled receptor (GPCR) activating numerous G

Indexed as

Receptor, Serotonin, 5-HT1AReceptors, G-Protein-CoupledSignal TransductionGTP-Binding ProteinsSerotoninGTP-Binding ProteinsReceptor, Serotonin, 5-HT1AReceptors, G-Protein-CoupledSerotonin

Identifiers

PMID37567783
PMCPMC10586511
OpenAlexW4385755392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.